The Comparative Safety of Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: A Meta-analysis Update of 44 Trials

American Journal of Medicine

Volumn 127, Issue 12, 2014, Pages 1208-1232

  Michaud, Tzeyu L ^a   Rho, Young Hee ^b   Shamliyan, Tatyana ^c   Kuntz, Karen M ^a   Choi, Hyon K ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c ELSEVIER MASSON   (France)

Author keywords

Adverse events; Meta analysis; Rheumatoid arthritis; Safety; Tumor necrosis factor inhibitors

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; PLACEBO; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G; MACROGOL DERIVATIVE; MONOCLONAL ANTIBODY; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ARTICLE; COMBINATION CHEMOTHERAPY; COMPARATIVE STUDY; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; INFECTION; META ANALYSIS; MONOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHEUMATOID ARTHRITIS; RISK ASSESSMENT; TREATMENT WITHDRAWAL; UNIVERSITY; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOGLOBULIN G; POLYETHYLENE GLYCOLS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84919626336     PISSN: 00029343     EISSN: 15557162     Source Type: Journal    
DOI: 10.1016/j.amjmed.2014.06.012     Document Type: Article

References (312)

1. P.C. Taylor, and M. Feldmann Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis Nat Rev Rheumatol 5 2009 578 582
2. T. Bongartz, A.J. Sutton, M.J. Sweeting, I. Buchan, E.L. Matteson, and V. Montori Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies JAMA 295 2006 2275
3. J.P. Leombruno, T.R. Einarson, and E.C. Keystone The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events Ann Rheum Dis 68 2009 1136 1145
4. A.E. Thompson, S.W. Rieder, and J.E. Pope Tumor necrosis factor therapy and the risk of serious infection and malignancy in patients with early rheumatoid arthritis: a meta-analysis of randomized controlled trials Arthritis Rheum 63 2011 1479 1485
5. J.A. Singh, G.A. Wells, and R. Christensen Adverse effects of biologics: a network meta-analysis and Cochrane overview Cochrane Database Syst Rev 2 2011 CD008794
6. K.J. Aaltonen, L.M. Virkki, A. Malmivaara, Y.T. Konttinen, D.C. Nordström, and M. Blom Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis PLoS One 7 2012 e30275
7. M.A. Lopez-Olivo, J.H. Tayar, and J.A. Martinez-Lopez Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis JAMA 308 2012 898 908
8. J.A. Singh, R. Christensen, and A. Wells George Biologics for rheumatoid arthritis: an overview of Cochrane reviews Cochrane Database Syst Rev 4 2009 CD007848
9. D. Scott, and G. Kingsley Tumor necrosis factor inhibitors for rheumatoid arthritis N Engl J Med 355 2006 704 712
10. FDA. SIMPONI® (Golimumab) Summary Review. Available at: http://www.fda.gov/downloads/drugs/drugsafety/ucm152822.pdf. Accessed August 20, 2014.
11. FDA. CIMZIA® (certolizumab pegol)) Medication Guide. Available at: http://www.fda.gov/downloads/drugs/drugsafety/ucm088571.pdf. Accessed August 20, 2014.
12. C. Counsell Formulating questions and locating primary studies for inclusion in systematic reviews Ann Intern Med 127 1997 380 387
13. F. Arnett Revised criteria for the classification of rheumatoid arthritis Bull Rheum Dis 38 1989 1 6
14. K.G. Saag, G.G. Teng, and N.M. Patkar American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis Arthritis Care Res 59 2008 762 784
15. R. Westhovens, D. Yocum, and J. Han The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial Arthritis Rheum 54 2006 1075 1086
16. L. Klareskog, D. van der Heijde, and J.P. de Jager Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial Lancet 363 2004 675 681
17. National Cancer Institute. Available at: http://www.cancer.gov/dictionary?cdrid=45771. Accessed March 17, 2014.
18. Higgins J, Green S. Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. 2011. Available at: http://handbook.cochrane.org/. Accessed August 20, 2014.
19. G. Guyatt, A.D. Oxman, and E.A. Akl GRADE guidelines: 1. Introduction - GRADE evidence profiles and summary of findings tables J Clin Epidemiol 64 2011 383 394
20. H. Balshem, M. Helfand, and H.J. Schünemann GRADE guidelines: 3. Rating the quality of evidence J Clin Epidemiol 64 2011 401 406
21. A.D. Oxman, and G.W. Group Grading quality of evidence and strength of recommendations BMJ 328 2004 1490 1494
22. Higgins DJPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions. Available at: http://tectutorials.com/Resources/AHRQ%20Modules/UoCTrainingMaterials/CochraneHB/booktext.pdf. Accessed August 20, 2014.
23. A. Laupacis, D.L. Sackett, and R.S. Roberts An assessment of clinically useful measures of the consequences of treatment N Engl J Med 318 1988 1728
24. D.G. Altman Confidence intervals for the number needed to treat BMJ 317 1998 1309
25. R. Fu, G. Gartlehner, and M. Grant Conducting quantitative synthesis when comparing medical interventions: AHRQ and the Effective Health Care Program J Clin Epidemiol 64 2011 1187 1197
26. G. Rücker, G. Schwarzer, J. Carpenter, and I. Olkin Why add anything to nothing? The arcsine difference as a measure of treatment effect in meta analysis with zero cells Stat Med 28 2009 721 738
27. Deeks JJ, Higgins J, Altman DG. Analysing data and undertaking meta-analyses. Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series. Version 5.1.0 [updated March 2011]. Available at: http://handbook.cochrane.org/. Accessed August 20, 2014.
28. J. Higgins, S.G. Thompson, J.J. Deeks, and D.G. Altman Measuring inconsistency in meta-analyses BMJ 327 2003 557
29. J. Higgins, and S.G. Thompson Quantifying heterogeneity in a meta-analysis Stat Med 21 2002 1539 1558
30. B. Wallace, C. Schmid, J. Lau, and T. Trikalinos Meta-Analyst: software for meta-analysis of binary, continuous and diagnostic data BMC Med Res Methodol 9 2009 80
31. L.B. van de Putte, R. Rau, and F.C. Breedveld Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study Ann Rheum Dis 62 2003 1168 1177
32. M.E. Weinblatt, E.C. Keystone, and D.E. Furst Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial Arthritis Rheum 48 2003 35 45
33. E.C. Keystone, M.H. Schiff, and J.M. Kremer Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial Arthritis Rheum 50 2004 353 363
34. L.B. van de Putte, C. Atkins, and M. Malaise Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed Ann Rheum Dis 63 2004 508 516
35. N. Miyasaka Clinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: the CHANGE study Mod Rheumatol 18 2008 252 262
36. F.C. Breedveld, M.H. Weisman, and A.F. Kavanaugh The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment Arthritis Rheum 54 2006 26 37
37. H.Y. Kim, S.K. Lee, and Y.W. Song A randomized, double-blind, placebo-controlled, phase III study of the human anti-tumor necrosis factor antibody adalimumab administered as subcutaneous injections in Korean rheumatoid arthritis patients treated with methotrexate APLAR J Rheumatol 2007 9 16
38. V. Bejarano, M. Quinn, and P.G. Conaghan Effect of the early use of the anti-tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis Arthritis Rheum 59 2008 1467 1474
39. D.E. Furst, M.H. Schiff, and R.M. Fleischmann Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis) J Rheumatol 30 2003 2563 2571
40. A. Kavanaugh, R.M. Fleischmann, and P. Emery Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study Ann Rheum Dis 72 2013 64 71
41. J. Detert, H. Bastian, and J. Listing Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study Ann Rheum Dis 72 2013 844 850
42. L.W. Moreland, M.H. Schiff, and S.W. Baumgartner Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial Ann Intern Med 130 1999 478 486
43. J.M. Bathon, R.W. Martin, and R.M. Fleischmann A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis N Engl J Med 343 2000 1586 1593
44. B. Combe, C. Codreanu, and U. Fiocco Etanercept and sulfasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving sulfasalazine: a double-blind comparison Ann Rheum Dis 65 2006 1357 1362
45. D. van der Heijde, L. Klareskog, and V. Rodriguez-Valverde Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial Arthritis Rheum 54 2006 1063 1074
46. D. van der Heijde, L. Klareskog, and R. Landewé Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis Arthritis Rheum 2007 3928 3939
47. M.H. Weisman, H.E. Paulus, and F.X. Burch A placebo-controlled, randomized, double-blinded study evaluating the safety of etanercept in patients with rheumatoid arthritis and concomitant comorbid diseases Rheumatology (Oxford) 46 2007 1122 1125
48. P. Emery, F.C. Breedveld, and S. Hall Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial Lancet 372 2008 375 382
49. B. Combe, C. Codreanu, and U. Fiocco Efficacy, safety and patient-reported outcomes of combination etanercept and sulfasalazine versus etanercept alone in patients with rheumatoid arthritis: a double-blind randomised 2-year study Ann Rheum Dis 68 2009 1146 1152
50. P. Emery, F. Breedveld, and D. van der Heijde Two-year clinical and radiographic results with combination etanercept-methotrexate therapy versus monotherapy in early rheumatoid arthritis: a two-year, double-blind, randomized study Arthritis Rheum 62 2010 674 682
51. D. Hu, C. Bao, and S. Chen A comparison study of a recombinant tumor necrosis factor receptor: Fc fusion protein (rhTNFR: Fc) and methotrexate in treatment of patients with active rheumatoid arthritis in China Rheum Int 29 2009 297 303
52. L.W. Moreland, J.R. O'Dell, and H.E. Paulus A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of early aggressive rheumatoid arthritis trial Arthritis Rheum 64 2012 2824 2835
53. R.N. Maini, F.C. Breedveld, and J.R. Kalden Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis Arthritis Rheum 41 1998 1552 1563
54. R.N. Maini, E.W. St Clair, and F.C. Breedveld Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group Lancet 354 1999 1932 1939
55. P.E. Lipsky, D.M. van der Heijde, and E.W. St Clair Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group N Engl J Med 2000 1594 1602
56. R.N. Maini, F.C. Breedveld, and J.R. Kalden Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate Arthritis Rheum 50 2004 1051 1065
57. E.W. St Clair, D.M. van der Heijde, and J.S. Smolen Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial Arthritis Rheum 50 2004 3432 3443
58. F.C. Zhang, Y. Hou, and F. Huang Infliximab versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a preliminary study from China APLAR J Rheumatol 2006 127 130
59. M. Schiff, M. Keiserman, and C. Codding Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate Ann Rheum Dis 67 2008 1096 1103
60. R.F. van Vollenhoven, S. Ernestam, and P. Geborek Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial Lancet 374 2009 459 466
61. E. Choy, F. McKenna, and J. Vencovsky Certolizumab pegol plus MTX administered every 4 weeks is effective in patients with RA who are partial responders to MTX Rheumatology (Oxford) 51 2012 1226 1234
62. R. Fleischmann, J. Vencovsky, and R.F. van Vollenhoven Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study Ann Rheum Dis 68 2009 805 811
63. E. Keystone, D. Heijde, and D. Mason Jr. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study Arthritis Rheum 58 2008 3319 3329
64. J. Smolen, R.B. Landewe, and P. Mease Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial Ann Rheum Dis 68 2009 797 804
65. M.E. Weinblatt, R. Fleischmann, and T.W. Huizinga Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study Rheumatology (Oxford) 51 2012 2204 2214
66. P. Emery, R.M. Fleischmann, and L.W. Moreland Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis Arthritis Rheum 60 2009 2272 2283
67. J. Kay, E.L. Matteson, and B. Dasgupta Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study Arthritis Rheum 58 2008 964 975
68. E.C. Keystone, M.C. Genovese, and L. Klareskog Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study Ann Rheum Dis 68 2009 789 796
69. J. Kremer, C. Ritchlin, and A. Mendelsohn Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study Arthritis Rheum 62 2010 917 928
70. Y. Tanaka, M. Harigai, and T. Takeuchi Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: results of the GO-FORTH study Ann Rheum Dis 71 2012 817 824
71. M.E. Weinblatt, C.O. Bingham, and A.M. Mendelsohn Intravenous golimumab is effective in patients with active rheumatoid arthritis despite methotrexate therapy with responses as early as week 2: results of the phase 3, randomised, multicentre, double-blind, placebo-controlled GO-FURTHER trial Ann Rheum Dis 72 2013 381 389
72. T. Takeuchi, M. Harigai, and Y. Tanaka Golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior treatment with disease-modifying antirheumatic drugs: results of the phase 2/3, multicentre, randomised, double-blind, placebo-controlled GO-MONO study through 24 weeks Ann Rheum Dis 72 2013 1488 1495
73. Y.F. Chen, P. Jobanputra, and P. Barton A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness Health Technol Assess 10 2006 iii-iv, xi-xiii, 1-229
74. A. Alonso-Ruiz, J.I. Pijoan, E. Ansuategui, A. Urkaregi, M. Calabozo, and A. Quintana Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety BMC Musculoskelet Disord 9 2008 52
75. T. Bongartz, F.C. Warren, D. Mines, E.L. Matteson, K.R. Abrams, and A.J. Sutton Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials Ann Rheum Dis 68 2009 1177 1183
76. J.A. Singh, R. Christensen, and G.A. Wells A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview CMAJ 181 2009 787 796
77. A. Wiens, C.J. Correr, R. Pontarolo, R. Venson, J.V. Quinalha, and M.F. Otuki A systematic review and meta-analysis of the efficacy and safety of etanercept for treating rheumatoid arthritis Scand J Immunol 70 2009 337 344
78. A. Wiens, C.J. Correr, R. Venson, M.C. Grochocki, M.F. Otuki, and R. Pontarolo A meta-analysis of the efficacy and safety of using infliximab for the treatment of rheumatoid arthritis Clin Rheumatol 28 2009 1365 1373
79. J.A. Singh, S. Noorbaloochi, and G. Singh Golimumab for rheumatoid arthritis Cochrane Database Syst Rev 1 2010 CD008341
80. A. Wiens, R. Venson, C.J. Correr, M.F. Otuki, and R. Pontarolo Meta-analysis of the efficacy and safety of adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis Pharmacotherapy 30 2010 339 353
81. J. Askling, K. Fahrbach, B. Nordstrom, S. Ross, C.H. Schmid, and D. Symmons Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data Pharmacoepidemiol Drug Saf 20 2011 119 130
82. V. Ruiz Garcia, P. Jobanputra, and A. Burls Certolizumab pegol (CDP870) for rheumatoid arthritis in adults Cochrane Database Syst Rev 2 2011 CD007649
83. A. Lethaby, M. Lopez-Olivo, L. Maxwell, A. Burls, P. Tugwell, and G. Wells Etanercept for the treatment of rheumatoid arthritis Cochrane Database Syst Rev 5 2013 CD004525
84. W. Dixon, K. Watson, M. Lunt, K. Hyrich, A. Silman, and D. Symmons Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register Arthritis Rheum 54 2006 2368 2376
85. F. Wolfe, L. Caplan, and K. Michaud Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy Arthritis Rheum 54 2006 628 634
86. J. Listing, A. Strangfeld, and S. Kary Infections in patients with rheumatoid arthritis treated with biologic agents Arthritis Rheum 52 2005 3403 3412
87. T. Abe, T. Takeuchi, and N. Miyasaka A multicenter, double-blind, randomized, placebo controlled trial of infliximab combined with low dose methotrexate in Japanese patients with rheumatoid arthritis J Rheumatol 33 2006 37 44
88. L. Abrahamyan, J. Beyene, and J. Feng Response times follow lognormal or gamma distribution in arthritis patients J Clin Epidemiol 63 2010 1363 1369
89. D. Aletaha, J. Funovits, F.C. Breedveld, J. Sharp, O. Segurado, and J.S. Smolen Rheumatoid arthritis joint progression in sustained remission is determined by disease activity levels preceding the period of radiographic assessment Arthritis Rheum 2009 1242 1249
90. C.F. Allaart, F.C. Breedveld, and B.A. Dijkmans Treatment of recent-onset rheumatoid arthritis: lessons from the BeSt study J Rheumatol Suppl 2007 25 33
91. C.F. Allaart, Y.P. Goekoop-Ruiterman, J.K. de Vries-Bouwstra, F.C. Breedveld, and B.A. Dijkmans Aiming at low disease activity in rheumatoid arthritis with initial combination therapy or initial monotherapy strategies: the BeSt study Clin Exp Rheumatol 24 6 Suppl 43 2006 S77 82
92. A. Anis, W. Zhang, and P. Emery The effect of etanercept on work productivity in patients with early active rheumatoid arthritis: results from the COMET study Rheumatology (Oxford) 48 2009 1283 1289
93. C. Antoni, and J.R. Kalden Combination therapy of the chimeric monoclonal anti-tumor necrosis factor alpha antibody (infliximab) with methotrexate in patients with rheumatoid arthritis Clin Exp Rheumatol 1999 S73 77
94. C.E. Antoni, A. Kavanaugh, and B. Kirkham Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT) Arthritis Rheum 52 2005 1227 1236
95. J.F. Baker, D.G. Baker, G. Toedter, J. Shults, J.M. Von Feldt, and M.B. Leonard Associations between vitamin D, disease activity, and clinical response to therapy in rheumatoid arthritis Clin Exp Rheumatol 30 2012 658 664
96. A.D. Bankhurst Etanercept and methotrexate combination therapy Clin Exp Rheumatol 17 6 Suppl 18 1999 S69 72
97. J.M. Bathon, R.M. Fleischmann, and D. Van der Heijde Safety and efficacy of etanercept treatment in elderly subjects with rheumatoid arthritis J Rheumatol 33 2006 234 243
98. S.W. Baumgartner, R.M. Fleischmann, L.W. Moreland, M.H. Schiff, J. Markenson, and J.B. Whitmore Etanercept (Enbrel) in patients with rheumatoid arthritis with recent onset versus established disease: improvement in disability J Rheumatol 31 2004 1532 1537
99. V. Bejarano, P.G. Conaghan, M.A. Quinn, B. Saleem, and P. Emery Benefits 8 years after a remission induction regime with an infliximab and methotrexate combination in early rheumatoid arthritis Rheumatology (Oxford) 49 2010 1971 1974
100. K. Bendtzen, P. Geborek, M. Svenson, L. Larsson, M.C. Kapetanovic, and T. Saxne Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab Arthritis Rheum 54 2006 3782 3789
101. M. Benucci, G. Saviola, P. Baiardi, M. Manfredi, P. Sarzi-Puttini, and F. Atzeni Efficacy and safety of leflunomide or methotrexate plus subcutaneous tumour necrosis factor-alpha blocking agents in rheumatoid arthritis Int J Immunopathol Pharmacol 24 2011 269 274
102. A.D. Billiau, M. Loop, and P.Q. Le Etanercept improves linear growth and bone mass acquisition in MTX-resistant polyarticular-course juvenile idiopathic arthritis Rheumatology (Oxford) 2010 1550 1558
103. H. Bliddal, L. Terslev, and E. Qvistgaard A randomized, controlled study of a single intra-articular injection of etanercept or glucocorticosteroids in patients with rheumatoid arthritis Scand J Rheumatol 35 2006 341 345
104. B.B.T.B. Blumenauer, A. Cranney, and A. Burls Etanercept for the treatment of rheumatoid arthritis Cochrane Database Syst Rev 2003 (3)
105. B.B.T.B. Blumenauer, M. Judd, and A. Wells George Inxfliximab for the treatment of rheumatoid arthritis Cochrane Database Syst Rev 2002 (3)
106. M. Boesen, L. Boesen, and K.E. Jensen Clinical outcome and imaging changes after intraarticular (IA) application of etanercept or methylprednisolone in rheumatoid arthritis: magnetic resonance imaging and ultrasound-Doppler show no effect of IA injections in the wrist after 4 weeks J Rheumatol 35 2008 584 591
107. F.C. Breedveld, P. Emery, and E. Keystone Infliximab in active early rheumatoid arthritis Ann Rheum Dis 63 2004 149 155
108. F.C. Breedveld, C. Han, and M. Bala Association between baseline radiographic damage and improvement in physical function after treatment of patients with rheumatoid arthritis Ann Rheum Dis 2005 52 55
109. H.I. Brunner, D.J. Lovell, B.K. Finck, and E.H. Giannini Preliminary definition of disease flare in juvenile rheumatoid arthritis J Rheumatol 2002 1058 1064
110. F. Capsoni, P. Sarzi-Puttini, and F. Atzeni Effect of adalimumab on neutrophil function in patients with rheumatoid arthritis Arthritis Res Ther 7 2005 R250 255
111. J. Chang, and L. Girgis Clinical use of anti-TNF-alpha biological agents-a guide for GPs Aust Fam Physician 36 2007 1035 1038
112. D.Y. Chen, S.J. Chou, and T.Y. Hsieh Randomized, double-blind, placebo-controlled, comparative study of human anti-TNF antibody adalimumab in combination with methotrexate and methotrexate alone in Taiwanese patients with active rheumatoid arthritis J Formos Med Assoc 108 2009 310 319
113. H.A. Chen, K.C. Lin, and C.H. Chen The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis Ann Rheum Dis 65 2006 35 39
114. E.H. Choy, B. Hazleman, and M. Smith Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial Rheumatology (Oxford) 41 2002 1133 1137
115. W. Clark, P. Jobanputra, P. Barton, and A. Burls The clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults: a systematic review and economic analysis Health Technol Assess 8 2004 iii-iv, ix-x, 1-105
116. P.G. Conaghan, P. Emery, and M. Ostergaard Assessment by MRI of inflammation and damage in rheumatoid arthritis patients with methotrexate inadequate response receiving golimumab: results of the GO-FORWARD trial Ann Rheum Dis 70 2011 1968 1974
117. L.A. Criswell, R.F. Lum, and K.N. Turner The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept Arthritis Rheum 2004 2750 2756
118. G. Cuomo, G. Molinaro, G. La Montagna, S. Migliaresi, and G. Valentini [A comparison between the Simplified Disease Activity Index (SDAI) and the Disease Activity Score (DAS28) as measure of response to treatment in patients undergoing different therapeutic regimens] Reumatismo 2006 22 25
119. J.R. Curtis, K. Luijtens, and A. Kavanaugh Predicting future response to certolizumab pegol in rheumatoid arthritis patients: features at 12 weeks associated with low disease activity at 1 year Arthritis Care Res (Hoboken) 64 2012 658 667
120. J.C. Davis Jr., D. Van Der Heijde, and J. Braun Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial Arthritis Rheum 48 2003 3230 3236
121. L. De Filippis, A. Caliri, S. Anghelone, G. Scibilia, R. Lo Gullo, and G. Bagnato Improving outcomes in tumour necrosis factor a treatment: comparison of the efficacy of the tumour necrosis factor a blocking agents etanercept and infliximab in patients with active rheumatoid arthritis Panminerva Med 48 2006 129 135
122. R. De Stefano, E. Frati, and F. Nargi Comparison of combination therapies in the treatment of rheumatoid arthritis: leflunomide-anti-TNF-alpha versus methotrexate-anti-TNF-alpha Clin Rheumatol 29 2010 517 524
123. J.K. de Vries-Bouwstra, Y.P. Goekoop-Ruiterman, and K.N. Verpoort Progression of joint damage in early rheumatoid arthritis: association with HLA-DRB1, rheumatoid factor, and anti-citrullinated protein antibodies in relation to different treatment strategies Arthritis Rheum 58 2008 1293 1298
124. I. Delabaye, and F. De Keyser 74-week follow-up of safety of infliximab in patients with refractory rheumatoid arthritis Arthritis Res Ther 12 2010 R121
125. A. den Broeder, L. van de Putte, and R. Rau A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis J Rheumatol 29 2002 2288 2298
126. E.M. Dias, C. Lukas, R. Landewé, S. Fatenejad, and D. van der Heijde Reliability and sensitivity to change of the Simple Erosion Narrowing Score compared with the Sharp-van der Heijde method for scoring radiographs in rheumatoid arthritis Ann Rheum Dis 2008 375 379
127. P. Durez, J. Malghem, and A. Nzeusseu Toukap Treatment of early rheumatoid arthritis: a randomized magnetic resonance imaging study comparing the effects of methotrexate alone, methotrexate in combination with infliximab, and methotrexate in combination with intravenous pulse methylprednisolone Arthritis Rheum 56 2007 3919 3927
128. P. Durez, A. Nzeusseu Toukap, and B.R. Lauwerys A randomised comparative study of the short term clinical and biological effects of intravenous pulse methylprednisolone and infliximab in patients with active rheumatoid arthritis despite methotrexate treatment Ann Rheum Dis 63 2004 1069 1074
129. M.J. Elliott, R.N. Maini, and M. Feldmann Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis Lancet 344 1994 1105 1110
130. P. Emery, R. Fleischmann, and D. van der Heijde The effects of golimumab on radiographic progression in rheumatoid arthritis: results of randomized controlled studies of golimumab before methotrexate therapy and golimumab after methotrexate therapy Arthritis Rheum 63 2011 1200 1210
131. P. Emery, M.C. Genovese, R. van Vollenhoven, J.T. Sharp, K. Patra, and E.H. Sasso Less radiographic progression with adalimumab plus methotrexate versus methotrexate monotherapy across the spectrum of clinical response in early rheumatoid arthritis J Rheumatol 36 2009 1429 1441
132. P. Emery, D. van der Heijde, and M. Ostergaard Exploratory analyses of the association of MRI with clinical, laboratory and radiographic findings in patients with rheumatoid arthritis Ann Rheum Dis 70 2011 2126 2130
133. M. Englbrecht, Y. Wang, and M. Ronneberger Measuring joint involvement in polyarticular psoriatic arthritis: an introduction of alternatives Arthritis Care Res (Hoboken) 2010 977 983
134. I.L. Engvall, B. Tengstrand, K. Brismar, and I. Hafstrom Infliximab therapy increases body fat mass in early rheumatoid arthritis independently of changes in disease activity and levels of leptin and adiponectin: a randomised study over 21 months Arthritis Res Ther 12 2010 R197
135. P. Farahani, M. Levine, and R. Goeree A comparison between integrating clinical practice setting and randomized controlled trial setting into economic evaluation models of therapeutics J Eval Clin Pract 2006 463 470
136. A.A. Fasanmade, O.J. Adedokun, and J. Ford Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis Eur J Clin Pharmacol 65 2009 1211 1228
137. C. Fernandez-Lopez, and F.J. Blanco [ATTAIN study: efficacy of abatacept in patients with rheumatoid arthritis and inadequate response to anti-TNF-alpha] Reumatol Clin Suppl 2006 34 43
138. H.G. Flint-Wagner, J. Lisse, and T.G. Lohman Assessment of a sixteen-week training program on strength, pain, and function in rheumatoid arthritis patients J Clin Rheumatol 15 2009 165 171
139. J.S. Smolen, C. Han, and D.M. van der Heijde Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade Ann Rheum Dis 68 2009 823 827
140. D.E. Furst, N. Gaylis, and V. Bray Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study Ann Rheum Dis 66 2007 893 899
141. P. Garnero, E. Gineyts, S. Christgau, B. Finck, and P.D. Delmas Association of baseline levels of urinary glucosyl-galactosyl-pyridinoline and type II collagen C-telopeptide with progression of joint destruction in patients with early rheumatoid arthritis Arthritis Rheum 46 2002 21 30
142. M.C. Genovese, J.M. Bathon, and R.M. Fleischmann Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis J Rheumatol 32 2005 1232 1242
143. M.C. Genovese, J.M. Bathon, and R.W. Martin Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes Arthritis Rheum 46 2002 1443 1450
144. M.C. Genovese, J.C. Becker, and M. Schiff Abatacept for rheumatoid arthritis refractory to tumor necrosis factor a inhibition N Engl J Med 2005 1114 1123
145. M.C. Genovese, S. Cohen, and L. Moreland Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate Arthritis Rheum 50 2004 1412 1419
146. M.C. Genovese, C. Han, and E.C. Keystone Effect of golimumab on patient-reported outcomes in rheumatoid arthritis: results from the GO-FORWARD study J Rheumatol 39 2012 1185 1191
147. D.M. Gerlag, S. Hollis, and M. Layton Preclinical and clinical investigation of a CCR5 antagonist, AZD5672, in patients with rheumatoid arthritis receiving methotrexate Arthritis Rheum 2010 3154 3160
148. Y.P. Goekoop-Ruiterman, J.K. de Vries-Bouwstra, and C.F. Allaart Patient preferences for treatment: report from a randomised comparison of treatment strategies in early rheumatoid arthritis (BeSt trial) Ann Rheum Dis 66 2007 1227 1232
149. Y.P. Goekoop-Ruiterman, J.K. de Vries-Bouwstra, and C.F. Allaart Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial Ann Intern Med 2007 406 415
150. Y.P. Goekoop-Ruiterman, J.K. de Vries-Bouwstra, and C.F. Allaart Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial Arthritis Rheum 52 2005 3381 3390
151. J.A. Goldman, H.A. Xia, B. White, and H. Paulus Evaluation of a modified ACR20 scoring system in patients with rheumatoid arthritis receiving treatment with etanercept Ann Rheum Dis 65 2006 1649 1652
152. M. Guler-Yuksel, C.F. Allaart, and I. Watt Treatment with TNF-alpha inhibitor infliximab might reduce hand osteoarthritis in patients with rheumatoid arthritis Osteoarthritis Cartilage 18 2010 1256 1262
153. M. Guler-Yuksel, J. Bijsterbosch, and Y.P. Goekoop-Ruiterman Changes in bone mineral density in patients with recent onset, active rheumatoid arthritis Ann Rheum Dis 67 2008 823 828
154. M. Guler-Yuksel, N.B. Klarenbeek, and Y.P. Goekoop-Ruiterman Accelerated hand bone mineral density loss is associated with progressive joint damage in hands and feet in recent-onset rheumatoid arthritis Arthritis Res Ther 12 2010 R96
155. C. Han, M.U. Rahman, and M.K. Doyle Association of anemia and physical disability among patients with rheumatoid arthritis J Rheumatol 34 2007 2177 2182
156. C. Han, J. Smolen, A. Kavanaugh, E.W. St Clair, D. Baker, and M. Bala Comparison of employability outcomes among patients with early or long-standing rheumatoid arthritis Arthritis Rheum 59 2008 510 514
157. S.B. Hanauer, B.G. Feagan, and G.R. Lichtenstein Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial Lancet 2002 1541 1549
158. U. Hasan Tumour necrosis factor inhibitors-what we need to know N Z Med J 119 2006 U2336
159. G. Haugeberg, P.G. Conaghan, M. Quinn, and P. Emery Bone loss in patients with active early rheumatoid arthritis: infliximab and methotrexate compared with methotrexate treatment alone. Explorative analysis from a 12-month randomised, double-blind, placebo-controlled study Ann Rheum Dis 68 2009 1898 1901
160. M. Hoff, T.K. Kvien, J. Kalvesten, A. Elden, and G. Haugeberg Adalimumab therapy reduces hand bone loss in early rheumatoid arthritis: explorative analyses from the PREMIER study Ann Rheum Dis 68 2009 1171 1176
161. M. Hoff, T.K. Kvien, J. Kalvesten, A. Elden, A. Kavanaugh, and G. Haugeberg Adalimumab reduces hand bone loss in rheumatoid arthritis independent of clinical response: subanalysis of the PREMIER study BMC Musculoskelet Disord 12 2011 54
162. E.C. Hsia, J.J. Cush, and E.L. Matteson Comprehensive tuberculosis screening program in patients with inflammatory arthritides treated with golimumab, a human anti-tumor necrosis factor antibody, in Phase III clinical trials Arthritis Care Res (Hoboken) 65 2013 309 313
163. C. Hu, Z. Xu, Y. Zhang, M.U. Rahman, H.M. Davis, and H. Zhou Population approach for exposure-response modeling of golimumab in patients with rheumatoid arthritis J Clin Pharmacol 51 2011 639 648
164. S. Jamal, K. Patra, and E.C. Keystone Adalimumab response in patients with early versus established rheumatoid arthritis: DE019 randomized controlled trial subanalysis Clin Rheumatol 28 2009 413 419
165. K.A. Jenks, L.K. Stamp, J.L. O'Donnell, R.L. Savage, and P.T. Chapman Leflunomide-associated infections in rheumatoid arthritis J Rheumatol 34 2007 2201 2203
166. A.K. Johnsen, M.H. Schiff, and P.J. Mease Comparison of 2 doses of etanercept (50 vs 100 mg) in active rheumatoid arthritis: a randomized double blind study J Rheumatol 33 2006 659 664
167. M.S. Joy, D.S. Gipson, and L. Powell Phase 1 trial of adalimumab in Focal Segmental Glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) study group Am J Kidney Dis 55 2010 50 60
168. J.L. Kaine, A.J. Kivitz, C. Birbara, and A.Y. Luo Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab J Rheumatol 34 2007 272 279
169. H. Kameda, Y. Ueki, and K. Saito Etanercept (ETN) with methotrexate (MTX) is better than ETN monotherapy in patients with active rheumatoid arthritis despite MTX therapy: a randomized trial Mod Rheumatol 20 2010 531 538
170. P. Karaca-Mandic, G.F. Joyce, D.P. Goldman, and M. Laouri Cost sharing, family health care burden, and the use of specialty drugs for rheumatoid arthritis Health Serv Res 45 5 Pt 1 2010 1227 1250
171. W. Katchamart, J. Trudeau, V. Phumethum, and C. Bombardier Methotrexate monotherapy versus methotrexate combination therapy with non-biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis Cochrane Database Syst Rev 4 2010 CD008495
172. A. Kavanaugh, L. Klareskog, D. van der Heijde, J. Li, B. Freundlich, and M. Hooper Improvements in clinical response between 12 and 24 weeks in patients with rheumatoid arthritis on etanercept therapy with or without methotrexate Ann Rheum Dis 67 2008 1444 1447
173. A. Kavanaugh, J.S. Smolen, and P. Emery Effect of certolizumab pegol with methotrexate on home and work place productivity and social activities in patients with active rheumatoid arthritis Arthritis Rheum 61 2009 1592 1600
174. A. Kavanaugh, E.W. St Clair, W.J. McCune, T. Braakman, and P. Lipsky Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy J Rheumatol 27 2000 841 850
175. J. Kekow, R.J. Moots, and P. Emery Patient-reported outcomes improve with etanercept plus methotrexate in active early rheumatoid arthritis and the improvement is strongly associated with remission: the COMET trial Ann Rheum Dis 69 2010 222 225
176. E. Keystone, B. Freundlich, M. Schiff, J. Li, and M. Hooper Patients with moderate rheumatoid arthritis (RA) achieve better disease activity states with etanercept treatment than patients with severe RA J Rheumatol 36 2009 522 531
177. E. Keystone, M.C. Genovese, and L. Klareskog Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study Ann Rheum Dis 2010 1129 1135
178. E.C. Keystone, B. Combe, and J. Smolen Sustained efficacy of certolizumab pegol added to methotrexate in the treatment of rheumatoid arthritis: 2-year results from the RAPID 1 trial Rheumatology (Oxford) 51 2012 1628 1638
179. E.C. Keystone, J.R. Curtis, and R.M. Fleischmann Rapid improvement in the signs and symptoms of rheumatoid arthritis following certolizumab pegol treatment predicts better longterm outcomes: post-hoc analysis of a randomized controlled trial J Rheumatol 38 2011 990 996
180. E.C. Keystone, B. Haraoui, and V.P. Bykerk Role of adalimumab in the treatment of early rheumatoid arthritis Clin Exp Rheumatol 2003 S198 199
181. E.C. Keystone, A. Kavanaugh, M.E. Weinblatt, K. Patra, and A.L. Pangan Clinical consequences of delayed addition of adalimumab to methotrexate therapy over 5 years in patients with rheumatoid arthritis J Rheumatol 38 2011 855 862
182. E.C. Keystone, M.H. Schiff, and J.M. Kremer Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial Arthritis Rheum 50 2004 353 363
183. M. Kimel, M. Cifaldi, N. Chen, and D. Revicki Adalimumab plus methotrexate improved SF-36 scores and reduced the effect of rheumatoid arthritis (RA) on work activity for patients with early RA J Rheumatol 35 2008 206 215
184. R. Kirwan John, W.J. Bijlsma Johannes, M. Boers, and B. Shea Effects of glucocorticoids on radiological progression in rheumatoid arthritis Cochrane Database Syst Rev 1 2007 CD006356
185. N.B. Klarenbeek, M. Guler-Yuksel, and D.M. van der Heijde Clinical synovitis in a particular joint is associated with progression of erosions and joint space narrowing in that same joint, but not in patients initially treated with infliximab Ann Rheum Dis 69 2010 2107 2113
186. N.B. Klarenbeek, M. Guler-Yuksel, and S.M. van der Kooij The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study Ann Rheum Dis 70 2011 1039 1046
187. N.B. Klarenbeek, S.M. van der Kooij, and M. Guler-Yuksel Discontinuing treatment in patients with rheumatoid arthritis in sustained clinical remission: exploratory analyses from the BeSt study Ann Rheum Dis 70 2011 315 319
188. N.B. Klarenbeek, S.M. van der Kooij, and T.J. Huizinga Blood pressure changes in patients with recent-onset rheumatoid arthritis treated with four different treatment strategies: a post hoc analysis from the BeSt trial Ann Rheum Dis 2010 1342 1345
189. L. Klareskog, M. Gaubitz, V. Rodriguez-Valverde, M. Malaise, M. Dougados, and J. Wajdula A long-term, open-label trial of the safety and efficacy of etanercept (Enbrel) in patients with rheumatoid arthritis not treated with other disease-modifying antirheumatic drugs Ann Rheum Dis 65 2006 1578 1584
190. G. Kobelt, P. Lindgren, A. Singh, and L. Klareskog Cost effectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial Ann Rheum Dis 64 2005 1174 1179
191. M. Kosinski, S.C. Kujawski, and R. Martin Health-related quality of life in early rheumatoid arthritis: impact of disease and treatment response Am J Manag Care 8 2002 231 240
192. J.M. Kremer, B.J. Bloom, and F.C. Breedveld The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo Arthritis Rheum 60 2009 1895 1905
193. J.M. Kremer, M.E. Weinblatt, and A.D. Bankhurst Etanercept added to background methotrexate therapy in patients with rheumatoid arthritis: continued observations Arthritis Rheum 48 2003 1493 1499
194. P. Lahdenne, P. Vahasalo, and V. Honkanen Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label study Ann Rheum Dis 2003 245 247
195. J.L. Lan, S.J. Chou, D.Y. Chen, Y.H. Chen, T.Y. Hsieh, and M. Young Jr. A comparative study of etanercept plus methotrexate and methotrexate alone in Taiwanese patients with active rheumatoid arthritis: a 12-week, double-blind, randomized, placebo-controlled study J Formos Med Assoc 103 2004 618 623
196. R. Landewe, D. Van Der Heijde, L. Klareskog, R. Van Vollenhoven, and S. Fatenejad Disconnect between inflammation and joint destruction after treatment with etanercept plus methotrexate: Results from the trial of etanercept and methotrexate with radiographic and patient outcomes Arthritis Rheum 2006 3119 3125
197. H. Lee, H.C. Kimko, M. Rogge, D. Wang, I. Nestorov, and C.C. Peck Population pharmacokinetic and pharmacodynamic modeling of etanercept using logistic regression analysis Clin Pharmacol Ther 73 2003 348 365
198. Q. Lin, J.R. Gu, and T.W. Li Value of the peripheral blood B-cells subsets in patients with ankylosing spondylitis Chin Med J (Engl) 122 2009 1784 1789
199. Q. Lin, Z. Lin, and J. Gu Abnormal high-expression of CD154 on T lymphocytes of ankylosing spondylitis patients is down-regulated by etanercept treatment Rheumatol Int 30 2010 317 323
200. M.P. Lisbona, J. Maymo, J. Perich, M. Almirall, and J. Carbonell Rapid reduction in tenosynovitis of the wrist and fingers evaluated by MRI in patients with rheumatoid arthritis after treatment with etanercept Ann Rheum Dis 69 2010 1117 1122
201. M.P. Lisbona, J. Maymo, J. Perich, M. Almirall, C. Perez-Garcia, and J. Carbonell Etanercept reduces synovitis as measured by magnetic resonance imaging in patients with active rheumatoid arthritis after only 6 weeks J Rheumatol 35 2008 394 397
202. D.J. Lovell, E.H. Giannini, and A. Reiff Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group N Engl J Med 2000 763 769
203. D.J. Lovell, A. Reiff, and N.T. Ilowite Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis Arthritis Rheum 2008 1496 1504
204. D.J. Lovell, N. Ruperto, and S. Goodman Adalimumab with or without methotrexate in juvenile rheumatoid arthritis N Engl J Med 2008 810 820
205. C. Lukas, D. van der Heijde, S. Fatenajad, and R. Landewé Repair of erosions occurs almost exclusively in damaged joints without swelling Ann Rheum Dis 2010 851 855
206. W.P. Maksymowych, C. Mallon, and S. Morrow Development and validation of the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index Ann Rheum Dis 68 2009 948 953
207. W.P. Maksymowych, A.R. Poole, and L. Hiebert Etanercept exerts beneficial effects on articular cartilage biomarkers of degradation and turnover in patients with ankylosing spondylitis J Rheumatol 32 2005 1911 1917
208. W.P. Maksymowych, D. Salonen, R.D. Inman, P. Rahman, and R.G. Lambert Low-dose infliximab (3 mg/kg) significantly reduces spinal inflammation on magnetic resonance imaging in patients with ankylosing spondylitis: a randomized placebo-controlled study J Rheumatol 37 2010 1728 1734
209. S.M. Marcora, K.R. Chester, G. Mittal, A.B. Lemmey, and P.J. Maddison Randomized phase 2 trial of anti-tumor necrosis factor therapy for cachexia in patients with early rheumatoid arthritis Am J Clin Nutr 84 2006 1463 1472
210. X. Mariette, P. Ravaud, and S. Steinfeld Inefficacy of infliximab in primary Sjogren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjogren's Syndrome (TRIPSS) Arthritis Rheum 50 2004 1270 1276
211. S. Masiero, A. Boniolo, L. Wassermann, H. Machiedo, D. Volante, and L. Punzi Effects of an educational-behavioral joint protection program on people with moderate to severe rheumatoid arthritis: a randomized controlled trial Clin Rheumatol 26 2007 2043 2050
212. S.D. Mathias, H.H. Colwell, D.P. Miller, L.W. Moreland, M. Buatti, and L. Wanke Health-related quality of life and functional status of patients with rheumatoid arthritis randomly assigned to receive etanercept or placebo Clin Ther 22 2000 128 139
213. L. Maxwell, and A. Singh Jasvinder Abatacept for rheumatoid arthritis Cochrane Database Syst Rev 4 2009 CD007277
214. P.J. Mease Etanercept, a TNF antagonist for treatment for psoriatic arthritis and psoriasis Skin Therapy Lett 2003 1 4
215. P.J. Mease, B.S. Goffe, J. Metz, A. VanderStoep, B. Finck, and D.J. Burge Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial Lancet 356 2000 385 390
216. P.J. Mease, K. Hobbs, and A. Chalmers Local delivery of a recombinant adenoassociated vector containing a tumour necrosis factor alpha antagonist gene in inflammatory arthritis: a phase 1 dose-escalation safety and tolerability study Ann Rheum Dis 68 2009 1247 1254
217. P.A. Merkel, G.H. Lo, and J.T. Holbrook Brief communication: high incidence of venous thrombotic events among patients with Wegener granulomatosis: the Wegener's Clinical Occurrence of Thrombosis (WeCLOT) Study Ann Intern Med 142 2005 620 626
218. M. Mertens, and A. Singh Jasvinder Anakinra for rheumatoid arthritis Cochrane Database Syst Rev 1 2009 CD005121
219. L.W. Moreland, R.P. Bucy, M.E. Weinblatt, K.M. Mohler, G.T. Spencer-Green, and W.W. Chatham Immune function in patients with rheumatoid arthritis treated with etanercept Clin Immunol 103 2002 13 21
220. L.W. Moreland, M.C. Genovese, R. Sato, and A. Singh Effect of etanercept on fatigue in patients with recent or established rheumatoid arthritis Arthritis Rheum 55 2006 287 293
221. L.W. Moreland, M.E. Weinblatt, and E.C. Keystone Etanercept treatment in adults with established rheumatoid arthritis: 7 years of clinical experience J Rheumatol 33 2006 854 861
222. F. Navarro-Sarabia, R. Ariza-Ariza, B. Hernandez-Cruz, and I. Villanueva Adalimumab for treating rheumatoid arthritis Cochrane Database Syst Rev 3 2005 CD005113
223. I. Nestorov, R. Zitnik, T. DeVries, A.M. Nakanishi, A. Wang, and C. Banfield Pharmacokinetics of subcutaneously administered etanercept in subjects with psoriasis Br J Clin Pharmacol 62 2006 435 445
224. M. Osiri, B. Shea, and V. Welch Leflunomide for the treatment of rheumatoid arthritis Cochrane Database Syst Rev 3 2002
225. M. Ostergaard, P. Emery, and P.G. Conaghan Significant improvement in synovitis, osteitis, and bone erosion following golimumab and methotrexate combination therapy as compared with methotrexate alone: a magnetic resonance imaging study of 318 methotrexate-naive rheumatoid arthritis patients Arthritis Rheum 63 2011 3712 3722
226. K. Pavelka, K. Jarosova, and D. Suchy Increasing the infliximab dose in rheumatoid arthritis patients: a randomised, double blind study failed to confirm its efficacy Ann Rheum Dis 68 2009 1285 1289
227. L.C. Perera, K.E. Tymms, and B.J. Wilson Etanercept in severe active rheumatoid arthritis: first Australian experience Intern Med J 36 2006 625 631
228. D.J. Perkins, E.W. St Clair, M.A. Misukonis, and J.B. Weinberg Reduction of NOS2 overexpression in rheumatoid arthritis patients treated with anti-tumor necrosis factor alpha monoclonal antibody (cA2) Arthritis Rheum 41 1998 2205 2210
229. M.J. Peters, P. Watt, and L. Cherry Lack of effect of TNFalpha blockade therapy on circulating adiponectin levels in patients with autoimmune disease: results from two independent prospective studies Ann Rheum Dis 69 2010 1687 1690
230. T. Pincus, I. Amara, O.G. Segurado, M. Bergman, and G.G. Koch Relative efficiencies of physician/assessor global estimates and patient questionnaire measures are similar to or greater than joint counts to distinguish adalimumab from control treatments in rheumatoid arthritis clinical trials J Rheumatol 2008 201 205
231. M.A. Quinn, P.G. Conaghan, and P.J. O'Connor Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial Arthritis Rheum 52 2005 27 35
232. M.U. Rahman, I. Strusberg, and P. Geusens Double-blinded infliximab dose escalation in patients with rheumatoid arthritis Ann Rheum Dis 66 2007 1233 1238
233. R. Rau, S. Simianer, and P.L. van Riel Rapid alleviation of signs and symptoms of rheumatoid arthritis with intravenous or subcutaneous administration of adalimumab in combination with methotrexate Scand J Rheumatol 2004 145 153
234. V. Ruiz Garcia, P. Jobanputra, and A. Burls Certolizumab pegol (CDP870) for rheumatoid arthritis in adults Cochrane Database Syst Rev 2 2011 CD007649
235. N. Ruperto, D.J. Lovell, and R. Cuttica A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis Arthritis Rheum 2007 3096 3106
236. N. Ruperto, D.J. Lovell, and R. Cuttica Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension Ann Rheum Dis 2010 718 722
237. B. Saleem, S. Mackie, and M. Quinn Does the use of tumour necrosis factor antagonist therapy in poor prognosis, undifferentiated arthritis prevent progression to rheumatoid arthritis? Ann Rheum Dis 67 2008 1178 1180
238. W.J. Sandborn, S.B. Hanauer, and S. Katz Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial Gastroenterology 121 2001 1088 1094
239. V. Sankar, M.T. Brennan, and M.R. Kok Etanercept in Sjogren's syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial Arthritis Rheum 50 2004 2240 2245
240. J. Sany, M.J. Kaiser, C. Jorgensen, and G. Trape Study of the tolerance of infliximab infusions with or without betamethasone premedication in patients with active rheumatoid arthritis Ann Rheum Dis 64 2005 1647 1649
241. M. Scheinberg, L.S. Guedes-Barbosa, and C. Mangueira Yellow fever revaccination during infliximab therapy Arthritis Care Res (Hoboken) 62 2010 896 898
242. S. Schneeweiss, S. Setoguchi, and M.E. Weinblatt Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis Arthritis Rheum 56 2007 1754 1764
243. M. Schoels, D. Aletaha, J. Funovits, A. Kavanaugh, D. Baker, and J.S. Smolen Application of the DAREA/DAPSA score for assessment of disease activity in psoriatic arthritis Ann Rheum Dis 69 2010 1441 1447
244. H. Sennels, S. Sorensen, and M. Ostergaard Circulating levels of osteopontin, osteoprotegerin, total soluble receptor activator of nuclear factor-kappa B ligand, and high-sensitivity C-reactive protein in patients with active rheumatoid arthritis randomized to etanercept alone or in combination with methotrexate Scand J Rheumatol 37 2008 241 247
245. A. Singh Jasvinder, S. Beg, and A. Lopez-Olivo Maria Tocilizumab for rheumatoid arthritis Cochrane Database Syst Rev 7 2010 CD008331
246. J.A. Singh, R. Christensen, and A. Wells George Biologics for rheumatoid arthritis: an overview of Cochrane reviews Cochrane Database Syst Rev 4 2009 CD007848
247. J.A. Singh, S. Noorbaloochi, and G. Singh Golimumab for rheumatoid arthritis Cochrane Database Syst Rev 1 2010 CD008341
248. T.J. Smeets, M.C. Kraan, M.E. van Loon, and P.P. Tak Tumor necrosis factor alpha blockade reduces the synovial cell infiltrate early after initiation of treatment, but apparently not by induction of apoptosis in synovial tissue Arthritis Rheum 48 2003 2155 2162
249. J.A. Smith, D.J. Thompson, and S.M. Whitcup A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis Arthritis Rheum 2005 18 23
250. J.S. Smolen, and D. Aletaha Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: the role of acute-phase reactants Arthritis Rheum 63 2011 43 52
251. J.S. Smolen, C. Han, and M. Bala Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study Arthritis Rheum 52 2005 1020 1030
252. J.S. Smolen, C. Han, and D. van der Heijde Infliximab treatment maintains employability in patients with early rheumatoid arthritis Arthritis Rheum 54 2006 716 722
253. J.S. Smolen, J. Kay, and R.B. Landewe Golimumab in patients with active rheumatoid arthritis who have previous experience with tumour necrosis factor inhibitors: results of a long-term extension of the randomised, double-blind, placebo-controlled GO-AFTER study through week 160 Ann Rheum Dis 71 2012 1671 1679
254. Smolen JS, Kay J, Doyle MK, et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet. Jul 18 2009;374(9685):210-221.
255. J.S. Smolen, D.M. van der Heijde, and D. Aletaha Progression of radiographic joint damage in rheumatoid arthritis: independence of erosions and joint space narrowing Ann Rheum Dis 68 2009 1535 1540
256. J.S. Smolen, D.M. Van Der Heijde, and E.W. St Clair Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial Arthritis Rheum 54 2006 702 710
257. D.H. Solomon The comparative safety and effectiveness of TNF-alpha antagonists [corrected] J Manag Care Pharm 13 1 Suppl 2007 S7 18
258. M. Soubrier, C. Lukas, and J. Sibilia Disease activity score-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis: data from the GUEPARD trial and ESPOIR cohort Ann Rheum Dis 70 2011 611 615
259. M. Soubrier, X. Puechal, and J. Sibilia Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial Rheumatology (Oxford) 48 2009 1429 1434
260. M.M. Souto-Carneiro, V. Mahadevan, and K. Takada Alterations in peripheral blood memory B cells in patients with active rheumatoid arthritis are dependent on the action of tumour necrosis factor Arthritis Res Ther 11 2009 R84
261. E.W. St Clair, C.L. Wagner, and A.A. Fasanmade The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial Arthritis Rheum 2002 1451 1459
262. V. Strand, P. Mease, and G.R. Burmester Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized controlled trial Arthritis Res Ther 11 2009 R170
263. V. Strand, J.S. Smolen, and R.F. van Vollenhoven Certolizumab pegol plus methotrexate provides broad relief from the burden of rheumatoid arthritis: analysis of patient-reported outcomes from the RAPID 2 trial Ann Rheum Dis 70 2011 996 1002
264. H. Takahashi, K. Shigehara, and M. Yamamoto Interferon gamma assay for detecting latent tuberculosis infection in rheumatoid arthritis patients during infliximab administration Rheumatol Int 27 2007 1143 1148
265. T. Takeuchi, N. Miyasaka, K. Inoue, T. Abe, and T. Koike Impact of trough serum level on radiographic and clinical response to infliximab plus methotrexate in patients with rheumatoid arthritis: results from the RISING study Mod Rheumatol 19 2009 478 487
266. T. Takeuchi, N. Miyasaka, and Y. Tatsuki Baseline tumour necrosis factor alpha levels predict the necessity for dose escalation of infliximab therapy in patients with rheumatoid arthritis Ann Rheum Dis 70 2011 1208 1215
267. P.C. Taylor, C. Ritchlin, and A. Mendelsohn Maintenance of efficacy and safety with subcutaneous golimumab among patients with active rheumatoid arthritis who previously received intravenous golimumab J Rheumatol 38 2011 2572 2580
268. P.C. Taylor, A. Steuer, and J. Gruber Comparison of ultrasonographic assessment of synovitis and joint vascularity with radiographic evaluation in a randomized, placebo-controlled study of infliximab therapy in early rheumatoid arthritis Arthritis Rheum 2004 1107 1116
269. P.C. Taylor, A. Steuer, and J. Gruber Ultrasonographic and radiographic results from a two-year controlled trial of immediate or one-year-delayed addition of infliximab to ongoing methotrexate therapy in patients with erosive early rheumatoid arthritis Arthritis Rheum 2006 47 53
270. W.B. van den Hout, Y.P. Goekoop-Ruiterman, and C.F. Allaart Cost-utility analysis of treatment strategies in patients with recent-onset rheumatoid arthritis Arthritis Rheum 61 2009 291 299
271. A.E. van der Bijl, Y.P. Goekoop-Ruiterman, and J.K. de Vries-Bouwstra Infliximab and methotrexate as induction therapy in patients with early rheumatoid arthritis Arthritis Rheum 56 2007 2129 2134
272. D. van der Heijde, F.C. Breedveld, and A. Kavanaugh Disease activity, physical function, and radiographic progression after longterm therapy with adalimumab plus methotrexate: 5-year results of PREMIER J Rheumatol 37 2010 2237 2246
273. D. van der Heijde, G. Burmester, and J. Melo-Gomes Inhibition of radiographic progression with combination etanercept and methotrexate in patients with moderately active rheumatoid arthritis previously treated with monotherapy Ann Rheum Dis 2009 1113 1118
274. D. van der Heijde, G. Burmester, and J. Melo-Gomes The safety and efficacy of adding etanercept to methotrexate or methotrexate to etanercept in moderately active rheumatoid arthritis patients previously treated with monotherapy Ann Rheum Dis 67 2008 182 188
275. D. van der Heijde, E.C. Keystone, and J.R. Curtis Timing and magnitude of initial change in disease activity score 28 predicts the likelihood of achieving low disease activity at 1 year in rheumatoid arthritis patients treated with certolizumab pegol: a post-hoc analysis of the RAPID 1 trial J Rheumatol 39 2012 1326 1333
276. D. van der Heijde, L. Klareskog, and M. Boers Comparison of different definitions to classify remission and sustained remission: 1 year TEMPO results Ann Rheum Dis 64 2005 1582 1587
277. D. van der Heijde, L. Klareskog, and A. Singh Patient reported outcomes in a trial of combination therapy with etanercept and methotrexate for rheumatoid arthritis: the TEMPO trial Ann Rheum Dis 65 2006 328 334
278. D. van der Heijde, R. Landewe, and S. Einstein Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept Arthritis Rheum 58 2008 1324 1331
279. D. van der Heijde, R. Landewe, and L. Klareskog Presentation and analysis of data on radiographic outcome in clinical trials: experience from the TEMPO study Arthritis Rheum 52 2005 49 60
280. D. van der Heijde, R. Landewé, R. van Vollenhoven, S. Fatenejad, and L. Klareskog Level of radiographic damage and radiographic progression are determinants of physical function: a longitudinal analysis of the TEMPO trial Ann Rheum Dis 2008 1267 1270
281. S.M. van der Kooij, J.K. de Vries-Bouwstra, and Y.P. Goekoop-Ruiterman Patient-reported outcomes in a randomized trial comparing four different treatment strategies in recent-onset rheumatoid arthritis Arthritis Rheum 61 2009 4 12
282. S.M. van der Kooij, J.K. de Vries-Bouwstra, and Y.P. Goekoop-Ruiterman Limited efficacy of conventional DMARDs after initial methotrexate failure in patients with recent onset rheumatoid arthritis treated according to the disease activity score Ann Rheum Dis 66 2007 1356 1362
283. S.M. van der Kooij, Y.P. Goekoop-Ruiterman, and J.K. de Vries-Bouwstra Drug-free remission, functioning and radiographic damage after 4 years of response-driven treatment in patients with recent-onset rheumatoid arthritis Ann Rheum Dis 68 2009 914 921
284. S.M. van der Kooij, S. le Cessie, and Y.P. Goekoop-Ruiterman Clinical and radiological efficacy of initial vs delayed treatment with infliximab plus methotrexate in patients with early rheumatoid arthritis Ann Rheum Dis 68 2009 1153 1158
285. P.L. van Riel, B. Freundlich, and D. MacPeek Patient-reported health outcomes in a trial of etanercept monotherapy versus combination therapy with etanercept and methotrexate for rheumatoid arthritis: the ADORE trial Ann Rheum Dis 2008 1104 1110
286. P.L. van Riel, A.J. Taggart, and J. Sany Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: the ADORE study Ann Rheum Dis 65 2006 1478 1483
287. R.F. van Vollenhoven, M.A. Cifaldi, S. Ray, N. Chen, and M.H. Weisman Improvement in work place and household productivity for patients with early rheumatoid arthritis treated with adalimumab plus methotrexate: work outcomes and their correlations with clinical and radiographic measures from a randomized controlled trial companion study Arthritis Care Res (Hoboken) 62 2010 226 234
288. R.F. van Vollenhoven, D. Felson, V. Strand, M.E. Weinblatt, K. Luijtens, and E.C. Keystone American College of Rheumatology hybrid analysis of certolizumab pegol plus methotrexate in patients with active rheumatoid arthritis: data from a 52-week phase III trial Arthritis Care Res (Hoboken) 63 2011 128 134
289. R.F. van Vollenhoven, N. Kinnman, E. Vincent, S. Wax, and J. Bathon Atacicept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase II, randomized, placebo-controlled trial Arthritis Rheum 63 2011 1782 1792
290. N. Vastesaeger, S. Xu, D. Aletaha, E.W. St Clair, and J.S. Smolen A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis Rheumatology (Oxford) 48 2009 1114 1121
291. A.N. Vgontzas, E. Zoumakis, H.M. Lin, E.O. Bixler, G. Trakada, and G.P. Chrousos Marked decrease in sleepiness in patients with sleep apnea by etanercept, a tumor necrosis factor-alpha antagonist J Clin Endocrinol Metab 2004 4409 4413
292. K. Visser, Y.P. Goekoop-Ruiterman, and J.K. de Vries-Bouwstra A matrix risk model for the prediction of rapid radiographic progression in patients with rheumatoid arthritis receiving different dynamic treatment strategies: post hoc analyses from the BeSt study Ann Rheum Dis 69 2010 1333 1337
293. S. Visvanathan, G.F. Keenan, D.G. Baker, A.I. Levinson, and C.L. Wagner Response to pneumococcal vaccine in patients with early rheumatoid arthritis receiving infliximab plus methotrexate or methotrexate alone J Rheumatol 34 2007 952 957
294. S. Visvanathan, J.C. Marini, and J.S. Smolen Changes in biomarkers of inflammation and bone turnover and associations with clinical efficacy following infliximab plus methotrexate therapy in patients with early rheumatoid arthritis J Rheumatol 34 2007 1465 1474
295. S. Visvanathan, C. Wagner, and J. Rojas E-selectin, interleukin 18, serum amyloid a, and matrix metalloproteinase 9 are associated with clinical response to golimumab plus methotrexate in patients with active rheumatoid arthritis despite methotrexate therapy J Rheumatol 36 2009 1371 1379
296. S. Visvanathan, C. Wagner, and J. Smolen IgG and IgM anticardiolipin antibodies following treatment with infliximab plus methotrexate in patients with early rheumatoid arthritis Arthritis Rheum 2006 2840 2844
297. S.Y. Wang, Y.Y. Liu, and H. Ye Circulating Dickkopf-1 is correlated with bone erosion and inflammation in rheumatoid arthritis J Rheumatol 38 2011 821 827
298. M. Weinblatt, M. Schiff, and A. Goldman Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial Ann Rheum Dis 66 2007 228 234
299. M.E. Weinblatt, E.C. Keystone, D.E. Furst, A.F. Kavanaugh, E.K. Chartash, and O.G. Segurado Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study Ann Rheum Dis 65 2006 753 759
300. M.E. Weinblatt, J.M. Kremer, and A.D. Bankhurst A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate N Engl J Med 340 1999 253 259
301. M.E. Weinblatt, M.H. Schiff, and E.M. Ruderman Efficacy and safety of etanercept 50 mg twice a week in patients with rheumatoid arthritis who had a suboptimal response to etanercept 50 mg once a week: results of a multicenter, randomized, double-blind, active drug-controlled study Arthritis Rheum 58 2008 1921 1930
302. M.H. Weisman, L.W. Moreland, and D.E. Furst Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study Clin Ther 25 2003 1700 1721
303. R. Westhovens, F. Houssiau, and J. Joly A phase I study assessing the safety, clinical response, and pharmacokinetics of an experimental infliximab formulation for subcutaneous or intramuscular administration in patients with rheumatoid arthritis J Rheumatol 33 2006 847 853
304. F. Wolfe, and K. Michaud Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients Arthritis Rheum 50 2004 1740 1751
305. F. Wolfe, and K. Michaud The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation Arthritis Rheum 56 2007 1433 1439
306. M. Wong, S.P. Oakley, and L. Young Infliximab improves vascular stiffness in patients with rheumatoid arthritis Ann Rheum Dis 68 2009 1277 1284
307. K.L. Wood, C.A. Hage, and K.S. Knox Histoplasmosis after treatment with anti-tumor necrosis factor-alpha therapy Am J Respir Crit Care Med 167 2003 1279 1282
308. S. Yount, M.V. Sorensen, D. Cella, N. Sengupta, J. Grober, and E.K. Chartash Adalimumab plus methotrexate or standard therapy is more effective than methotrexate or standard therapies alone in the treatment of fatigue in patients with active, inadequately treated rheumatoid arthritis Clin Exp Rheumatol 25 2007 838 846
309. H. Zhou, M. Buckwalter, and J. Boni Population-based pharmacokinetics of the soluble TNFr etanercept: a clinical study in 43 patients with ankylosing spondylitis compared with post hoc data from patients with rheumatoid arthritis Int J Clin Pharmacol Ther 42 2004 267 276
310. H. Zhou, H. Jang, and R.M. Fleischmann Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis J Clin Pharmacol 47 2007 383 396
311. H. Zhou, P.R. Mayer, J. Wajdula, and S. Fatenejad Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis J Clin Pharmacol 44 2004 1235 1243
312. Y. Zhuang, Z. Xu, and B. Frederick Golimumab pharmacokinetics after repeated subcutaneous and intravenous administrations in patients with rheumatoid arthritis and the effect of concomitant methotrexate: an open-label, randomized study Clin Ther 34 2012 77 90